Acne is a very common non-infectious skin condition that is frequently treated in dermatological practices. Because acne is often chronic and may persist for years, safe and effective long-term maintenance therapy is often required. Given the increasing frequency of antibiotic-resistant bacteria and the gravity of the consequences of this trend, it behooves dermatologists to maximize use of non-antimicrobial therapy when treating acne.
INTRODUCTION
Antibiotic overuse and the development of antibiotic-resistant bacteria, coupled with a dearth of new antimicrobial agents, have resulted in a serious domestic and global threat [1] . The scale and magnitude of this threat is severe. A recent statement issued from the Centers for Disease Control reported that roughly 23,000 deaths occur annually in the USA alone as a direct result of antibiotic-resistant bacteria [1] . The trend of increasingly antibiotic-resistant bacteria is ongoing; even last-resort antibiotics, such as colistin, which are used to treat multidrug-resistant infections, are becoming ineffective. For example, E. coli harboring the MCR-1 plasmid, which confers resistance to colistin, has recently been discovered for the first time in a human in the USA [2] . Dermatologists are in a unique position to respond to the rising threat of antibiotic-resistant bacteria: dermatologists make up just 1% of all physicians but are responsible for 4.9% of antibiotic prescriptions [3] .
Dermatologists primarily prescribe
antibiotics for the treatment of acne, and this prescribing practice may have contributed to the rise of antibiotic resistance. Responsible antibiotic stewardship is increasingly becoming recognized as an important principle to incorporate into dermatology practices.
Acne is one of the most common skin disorders treated by dermatologists, affecting between 40-50 million Americans [4] . While acne is highly prevalent in youth with around 85% of teenagers affected at some point in time, its occurrence is not uncommon in adults [5, 6] . Antibiotic overuse in the treatment of acne has led to changing resistance patterns in P.
acnes. While only 20% of P. acnes showed antibiotic resistance in 1978, roughly 2/3 are resistant today [7] [8] [9] . Both systemic and topical antibiotics are capable of changing the antibiotic-resistance patterns in bacteria.
Topical erythromycin has been shown to produce overgrowth of antibiotic resistance bacteria both locally and at distant sites [10, 11] . Similar resistance trends are also likely to result from topical clindamycin monotherapy.
Collateral damage to normal skin flora also occurs as a result of antibiotic use. The normal skin biome serves as an innate defense, and changes in the skin biome brought on by antibiotics can increase the risk of colonization by pathologic organisms [12] . For example, long courses of tetracycline induce gram-negative bacterial overgrowth in the nares, and this is associated with gram-negative folliculitis [13, 14] . Antibiotics used in the treatment of acne are also associated with the overgrowth of Streptococcus pyogenes and Staphylococcus aureus in the oral pharynx, and these changes may be linked to clinical pharyngitis [15] [16] [17] . Furthermore, increased rates of antibiotic-resistant bacteria colonization is seen in family members of acne patients who are treated with antibiotics [18] .
Given the risk associated with antibiotic use, careful consideration must be given to the use of this class of medications when treating acne.
In this systematic review of the literature we present the efficacy data from randomized clinical trials investigating non-antimicrobial treatments for acne, highlighting the appropriate use of these treatments as alternatives to long courses of systemic antibiotics.
METHODS

Search Strategies
A comprehensive search of the English-language literature was performed on PubMed using the following search terms:
''acne,'' ''treatment'' and ''randomized'' as well as ''photodynamic therapy,'' ''blue light'' and ''zinc'' or ''peel''. Bibliographies of select publications were reviewed for eligible studies.
Data Sources
We 
Data Extraction
Data collection included the number of patients per treatment group, details of treatment regimens, severity and location of acne, change in TLC or ILC following treatment, and tolerability of treatment.
RESULTS
A total of 192 studies were found, of which 57 met the inclusion and exclusion criteria. Study size ranged from 10 to 3010 patients, and treatment duration ranged from 6 weeks to 6 months. When applicable, efficacy results from trials examining matching treatment regiments were reviewed together using a weighted average. Side effects related to light therapy limit its use. The incidence of adverse events, such as pain and burning, is relatively high in patients using PDT. Patients have also reported significant cutaneous erythema lasting for several days post treatment. Postinflammatory pigmentation alteration can also be associated with PDT treatment.
Treatment of acne with chemical peels involves application of a keratolytic agent such as salicylic acid or glycolic acid to promote desquamation. Glycolic acid and amino fruit acid peels used at increasing concentration applied over 24 weeks at 2-week intervals were moderately effective in decreasing non-inflammatory TLC (62.7% and 62.4%, respectively, at 6 months) [86] .
Lipohydroxy acid and salicylic acid peels applied over 12 weeks at 2-week intervals were also moderately effective in decreasing non-inflammatory TLC (55.6% and 48.5%, respectively, at 98 days) [87] .
DISCUSSION
Acne is a chronic, multifactorial skin disease that is very common and can lead to disfiguring scars. Because the pilosebaceous unit is the primary structure involved, acne most frequently occurs in areas of high pilosebaceous unit density such as the face, neck, chest and back [88] .
Acne pathogenesis is complex, and our understanding of this disease process continues to evolve. Comedogenesis is thought to be triggered by a combination of abnormal desquamation of lipid-laden keratinocytes within the sebaceous follicle plus sebaceous gland hyperactivity. Androgens, which control sebum production, are known to contribute to the disease process. Increased production and cohesion of the corneocytes narrow the pilosebaceous opening to the skin and result in a bottleneck phenomenon, thereby producing a microcomedone. As the comedone develops and expands, there can be disruption of the follicular epithelium with extrusion of sebum and corneocytes into the interstitium, thereby leading to an inflammatory response. P. acnes, which is a ubiquitous commensal gram-positive rod, is found in higher concentrations on acne-affected skin. P. acnes is also known to stimulate an inflammatory response and facilitate comedone rupture. While P. acnes is involved in the disease process, its density is not correlated with acne severity and acne may occur even without its presence. For example, microcomedones are known to form in children with early acne prior to P. acnes colonization [89] . Furthermore, eradicating P. acnes may improve acne but will not produce a ''cure'' of the disease [90] . Topical retinoid use is limited by skin irritation, erythema and peeling, all of which can be mitigated with the use of a less potent retinoid for initial therapy and by starting treatment with alternate evening use.
Tolerability can also be enhanced by using tretinoin-impregnated microsphere gel, which was specifically formulated to have decreased depth of penetration [93] . Improved tolerability is likely to increase patient compliance with treatment. Tretinoin and adapalene are pregnancy category C, while tazarotene is category X and must be avoided in pregnant patients.
Because retinoids improve the abnormal keratinization seen in acne, they also enhance the delivery and efficacy of other topical treatments such as benzoyl peroxide and topical antibiotics (Fig. 1) Isotretinoin, which is highly effective at producing long-lasting remission in patients with severe acne, works by shrinking sebaceous glands [124] . A typical starting dose is around 0.5 mg/kg/day, and this is increased, as tolerated by the patient, to a goal dose of 1.0 mg/kg/day [125] . Because there is an inverse relationship between a patient's cumulative dose and risk of relapse, it is recommended that patients reach a cumulative dose of 120-150 mg/kg before cessation of therapy [126] . Some authors have advocated for even higher cumulative doses up to 220 mg/kg as this appears to significantly decrease the risk of relapse without increasing serious treatment-related adverse events [127] .
Isotretinoin is known to have numerous side effects, the majority of which are temporary and resolve with discontinuation of therapy. Musculoskeletal aches, cheilitis, hypertriglyceridemia and ophthalmic symptoms are most common. While it has been suggested that there is a relationship between isotretinoin treatment and both inflammatory bowel disease and depression, the majority of studies have not found evidence to support any causal association [128] [129] [130] [131] . The most serious established risk of isotretinoin is that which is posed to the fetus. Because of the highly teratogenic effects of isotretinoin, all patients treated with isotretinoin must participate in the iPLEDGE system, and female patients of child-bearing potential must use effective contraception.
The treatment of acne in women requires important consideration, as women comprise over 60% of clinic visits for acne and have a higher incidence than men of late-onset acne developing after age 25 [132, 133] . Moreover, acne in women can be difficult to treat and can become persistent, and women are four times more likely to have severe acne than men [5] .
Cosmetics or skin care products used by women do not appear to be responsible for the increased prevalence of acne in women, and the microflora of the skin in women with late onset acne compared to adolescents with acne is essentially the same, indicating that the pathogenesis of acne is likely not related to microflora differences [133, 134] .
Androgens play a role in the development of acne through stimulation of sebaceous glands.
The importance of androgens in the pathogenesis of acne can be appreciated by the fact that androgen-insensitive subjects neither produce sebum nor develop acne and by the fact that hyperandrogenic states such as polycystic ovarian disease produce acne that is highly responsive to anti-androgen agents [135, 136] . Conditions such as polycystic ovarian syndrome can cause elevated androgen levels leading to acne development, and such conditions should be considered in women with late-onset acne that is resistant to conventional treatments. While most women with acne have normal levels of serum androgens, there may still be a hormonal acne trigger such as menstrual cycleassociated flares. This phenomenon can be explained by an increased androgen sensitivity in these individuals [137] .
COCs treat acne through their anti-androgenic properties. COCs contain estrogen and progestin, which cause an increase in sex hormone-binding globulin, which binds free androgens and also exerts a negative feedback to decrease ovarian androgen production. There are four currently FDA higher doses can cause diuresis, menstrual irregularities, and breast tenderness and enlargement [140] . A recent paper reported that there is no need for routine potassium monitoring for hyperkalemia in healthy young women taking spironolactone for acne [141] . Spironolactone has a black box warning, as it has been implicated as being a possible teratogen and thus should be avoided in pregnancy.
Topical Light therapy is a moderately to highly effective method for treating inflammatory acne. Light therapy treats acne primarily through activation of porphyrins, leading to the destruction of P. acnes. The longer wavelengths used in IPL may also destroy sebaceous glands. Of the light therapies, IPL appears to have the greatest therapeutic effect.
Both red and blue light are commonly used for acne treatment, and both appear to be more effective when combined with PDT. ALA, a commonly used photosensitizer, is taken up by sebaceous glands and produces reactive oxygen species (ROS) when activated by red or blue light [82] . These ROS then cause sebaceous gland damage and destruction of P. acnes. MAL, which is a commonly used photosensitizer outside of the US, has also been used in PDT for acne treatment and has demonstrated significant efficacy in decreasing ILC [146] . PDT shows great promise in treating acne ranging from mild to severe, but the optimal choice of photosensitizer and light source are topics still under investigation [19] .
Moreover, the side effects associated with PDT, including moderate to severe pain during treatment and post-treatment erythema, limit its use, and more effective solutions to address these side effects are necessary for this treatment modality to become more widely used. Intralesional steroid injection, using triamcinolone acetonide injected into the center of the acne lesion, can be useful in decreasing individual nodulocystic acne lesions, especially when desiring rapid resolution. However, steroid injections can cause local skin atrophy and telangiectasias; thus, care
should be taken to use this treatment modality sparingly [147] .
Microdermabrasion is a minimally invasive procedure that involves varying degrees of controlled abrasion of the skin to treat a variety of conditions. Although microdermabrasion is generally not used to treat acne vulgaris, it is a commonly employed technique for treating acne scars and can produce mild to moderate improvement in skin contour irregularities [148] .
CONCLUSION
Overuse of antibiotics has resulted in antibiotic-resistant bacteria, and this development poses a major public health concern for the future. Dermatologists play a vital role in addressing this problem by practicing proper stewardship in prescribing antibiotics.
It is important to realize that while antibiotics play a crucial role in the treatment of acne, they should be used judiciously. Finally, novel and promising non-antibiotic treatments are currently in development for acne treatment, and we anticipate that these will ultimately enhance the non-antibiotic treatment options available for acne patients.
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